teriparatide NDC 47781-652

NDC codes

FDA NDC Directory

Product NDC (as listed)47781-652Labeler and product segments. Claims need a package NDC.

Product NDC at billing width47781-0652Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
47781-652-89	47781065289	1 SYRINGE in 1 CARTON (47781-652-89) / 2.24 mL in 1 SYRINGEMarketed from Nov 14, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): teriparatide
Generic name (nonproprietary): teriparatide
Active ingredients: Teriparatide — 250 ug/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Alvogen, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 211939
Marketing start: Nov 14, 2019
Listing expires: Dec 31, 2026
Other FDA classes: Parathyroid Hormone (Chemical structure)
Identifiers: Product ID 47781-652_78a0b591-7cbc-7cd1-1b40-b83f3699c2cfSPL ID 78a0b591-7cbc-7cd1-1b40-b83f3699c2cfSPL set ID 1b007339-dd0d-f019-5e0a-9b1b0f75011cRxCUI 1435115UNII 10T9CSU89I
Pharmacologic class: Parathyroid Hormone Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N447781065289 followed by a unit qualifier and the quantity

Package 47781-0652-89. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 27, 2025.

Indications (excerpt from the label)

Teriparatide injection is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide injection reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoi…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 211939

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 211939
Product	Strength	Form · route	Labeler	Product NDC
Bonsityteriparatide	Teriparatide 250 ug/mL	Injection, SolutionSubcutaneous	Alvogen Inc.	47781-852